Sermorelin: Molecular Structure

Molecular Structure and Properties#

Sermorelin (GHRH(1-29)NH2) is a synthetic 29-amino acid peptide that represents the biologically active N-terminal fragment of human growth hormone-releasing hormone. Its molecular formula is C149H246N44O42S, with a molecular weight of 3357.88 Da. The peptide was originally synthesized in the 1980s following the identification and sequencing of native GHRH from pancreatic tumor extracts by two independent groups.

Amino Acid Sequence#

The complete sequence of sermorelin is:

Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2

Key structural features of the sequence include:

• Tyrosine at position 1 (Tyr1): Critical for receptor binding. N-terminal modifications significantly reduce biological activity
• Hydrophobic core (residues 4-10): The Ile-Phe-Thr-Asn-Ser-Tyr segment forms a critical hydrophobic interaction surface for GHRH receptor engagement
• Basic residues (Arg11, Lys12, Arg20, Lys21, Arg29): Contribute to receptor binding affinity and peptide solubility
• Methionine 27 (Met27): The sole sulfur-containing residue, susceptible to oxidation which can reduce biological activity
• C-terminal amidation (-NH2): Enhances metabolic stability and receptor binding compared to the free acid form

The first 29 amino acids of GHRH contain all the structural elements necessary for receptor binding and activation. The remaining 15 residues (30-44) of native GHRH do not contribute significantly to biological activity but provide some protection against enzymatic degradation.

Three-Dimensional Structure#

In aqueous solution, sermorelin adopts a predominantly alpha-helical conformation spanning approximately residues 6-29, with a more flexible N-terminal segment (residues 1-5). This amphipathic helical structure is essential for receptor recognition and binding. The hydrophobic face of the helix makes critical contacts with the transmembrane domains of the GHRH receptor, while the hydrophilic face remains solvent-exposed.

Nuclear magnetic resonance (NMR) studies have confirmed that the alpha-helical content of GHRH peptides correlates directly with their biological potency. Disruption of the helical structure through proline substitution or D-amino acid insertion at internal positions dramatically reduces receptor binding affinity.

Pharmacokinetics#

Absorption#

Following subcutaneous injection, sermorelin is absorbed into the systemic circulation with peak plasma concentrations typically achieved within 5-20 minutes. Bioavailability via the subcutaneous route is variable and has not been precisely quantified in large clinical studies, though it is sufficient to produce clinically meaningful GH responses.

Distribution#

Sermorelin distributes primarily to the hypothalamic-pituitary axis where it engages GHRH receptors. As a hydrophilic peptide, it does not readily cross the blood-brain barrier, which limits its direct CNS effects. The volume of distribution is relatively small, consistent with extracellular distribution.

Metabolism#

Sermorelin is rapidly degraded by dipeptidyl peptidase IV (DPP-IV), which cleaves the Tyr1-Ala2 bond at the N-terminus, and by other serum proteases. This rapid enzymatic degradation accounts for the short plasma half-life. The Met27 residue is also susceptible to oxidation in vivo, which further reduces biological activity.

Elimination#

The plasma half-life of sermorelin is approximately 10-20 minutes following intravenous administration. This short half-life necessitates daily subcutaneous injections for therapeutic use. Elimination occurs primarily through enzymatic degradation in plasma and tissues, with renal clearance of degradation products.

Chemical Stability#

Sermorelin in lyophilized form is relatively stable when stored at -20 degrees Celsius, maintaining potency for extended periods. Key stability considerations include:

• Oxidation sensitivity: The methionine at position 27 is prone to oxidation, forming methionine sulfoxide. This modification reduces but does not eliminate biological activity. Antioxidants and inert gas headspace can mitigate this issue
• Aggregation: At high concentrations or elevated temperatures, sermorelin can form oligomeric aggregates that reduce bioavailability
• pH sensitivity: Optimal stability is maintained at mildly acidic pH (4.0-5.0). Alkaline conditions accelerate degradation
• Light sensitivity: Tyrosine residues (positions 1 and 10) are susceptible to photo-oxidation; storage in amber vials is recommended

Reconstituted solutions should be refrigerated at 2-8 degrees Celsius and used within 14 days. Repeated freeze-thaw cycles should be avoided as they promote aggregation and loss of potency.

Structural Analogs and Modifications#

Several modified analogs of sermorelin have been developed to address its pharmacokinetic limitations:

The most clinically advanced analog is tesamorelin, which received FDA approval in 2010 for HIV-associated lipodystrophy. Its N-terminal modification with trans-3-hexenoic acid provides resistance to DPP-IV degradation while maintaining full GHRH receptor agonist activity.

Receptor Interactions#

The GHRH receptor (GHRH-R) belongs to the class B (secretin) family of G-protein coupled receptors. Sermorelin engages the large N-terminal extracellular domain of the receptor through its amphipathic helical region. Key binding interactions include:

• Residues 1-8 interact primarily with the transmembrane core and extracellular loops
• Residues 12-29 form extensive contacts with the N-terminal extracellular domain
• The N-terminal Tyr1 residue is essential for receptor activation (agonism) vs. mere binding

This binding pattern is consistent with the two-domain model proposed for class B GPCR activation, where the C-terminal helix of the peptide ligand provides initial binding affinity while the N-terminal residues drive receptor conformational changes necessary for G-protein coupling and signaling.

Related Reading#

• Sermorelin overview and research guide
• Peptides similar to Sermorelin
• Sermorelin research evidence